Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-E2-A1L9-01A-11R-A13Q-07

— · A

6c46e585-b315-5723-9214-f9fb6dc2b56b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
20

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
  • INTERFERON_ALPHA_RESPONSE+0.490
  • INTERFERON_GAMMA_RESPONSE+0.410
  • TGF_BETA_SIGNALING+0.390
  • ANGIOGENESIS+0.380
  • HEDGEHOG_SIGNALING+0.380
  • COAGULATION+0.350
  • NOTCH_SIGNALING+0.350
  • UV_RESPONSE_DN+0.310
  • APOPTOSIS+0.300

Top 10 suppressed

  • MYC_TARGETS_V2-0.540
  • E2F_TARGETS-0.470
  • G2M_CHECKPOINT-0.360
  • MYC_TARGETS_V1-0.260
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
  • MITOTIC_SPINDLE-0.210
  • DNA_REPAIR-0.170
  • UNFOLDED_PROTEIN_RESPONSE-0.170
  • MTORC1_SIGNALING-0.150
  • SPERMATOGENESIS-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-J2-8192-01A-11R-2241-07
lung-landscapes@6
—cohortA10.884
2SRR5088824
melanoma-umap@29
——0.883
3TCGA-CR-7386-01A-11R-2016-07
head-neck@1
——0.878
4sclc3472_S37.txt
lung-landscapes@6
—cohortMD20.874
5SRR35579819
breast-umap@18
—A0.874
6TCGA-AR-A24O-01A-11R-A169-07
breast-umap@18
—A0.871
7SRR25617929
breast-umap@18
—A0.871
8TCGA-46-3766-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.870
9BSR_03_0053_A6_S70
breast-umap@18
—A0.870
10BS_JWSR581E
brain-umap@2
low-grade glioma—0.865

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.580Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.490Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.410Idelalisib— uncovered
TGF_BETA_SIGNALING0.390Inavolisib— uncovered
ANGIOGENESIS0.380Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
COAGULATION0.350Binimetinib— uncovered
NOTCH_SIGNALING0.350Inavolisib— uncovered
UV_RESPONSE_DN0.310Inavolisib— uncovered
APOPTOSIS0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered
PROTEIN_SECRETION0.280Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.280Inavolisib— uncovered
COMPLEMENT0.270Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.230Inavolisib— uncovered
ALLOGRAFT_REJECTION0.160Idelalisib— uncovered
APICAL_JUNCTION0.160Inavolisib— uncovered
APICAL_SURFACE0.140Temsirolimus— uncovered
IL2_STAT5_SIGNALING0.130Idelalisib— uncovered